clazakizumab   Click here for help

GtoPdb Ligand ID: 9195

Synonyms: ALD-518 | ALD518 | BMS-945429
Immunopharmacology Ligand
Compound class: Antibody
Comment: Clazakizumab is an investigational, aglycosylated, humanized (from a rabbit parental antibody) monoclonal antibody targeting interleukin-6, with anti-inflammatory potential [2].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. BLAST peptide sequence analysis reveals identical matches with peptides claimed in patent US8062864 [3]. Results presented in the patent show that the preferred antibodies block interaction of IL-6 with the IL-6 receptor, but no precise binding affinity data is provided.
1. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. (2011)
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
Expert Opin Biol Ther, 11 (12): 1663-8. [PMID:21995322]
2. FitzGerald O. (2016)
Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?.
Nat Rev Rheumatol, 12 (6): 318-9. [PMID:27215204]
3. Garcia-Martinez L, Jensen AEC, Olson K, Dutzar B, Ojala E, Kovacevich B, Latham J, Smith JTL. (2011)
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies.
Patent number: US8062864. Assignee: Alderbio Holdings Llc. Priority date: 21/05/2007. Publication date: 22/11/2011.
4. Ma JD, Heavey SF, Revta C, Roeland EJ. (2014)
Novel investigational biologics for the treatment of cancer cachexia.
Expert Opin Biol Ther, 14 (8): 1113-20. [PMID:24707881]
5. Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. (2016)
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
Arthritis Rheumatol, 68 (9): 2163-73. [PMID:27059799]
6. Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. (2015)
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Arthritis Rheumatol, 67 (10): 2591-600. [PMID:26138593]